AstraZeneca India inks LoI with Strand Life Sciences

November 18, 2026 | Wednesday | News

For exploring opportunities to collaborate in healthcare in India

AstraZeneca India has signed a Letter of Intent (LOI) with Strand Life Sciences, a genomics research and diagnostics company and a subsidiary of Reliance Industries Limited, to explore opportunities to collaborate in healthcare in India.

The collaboration brings together AstraZeneca Pharma India and Strand Life Sciences in a healthcare-focused partnership.

The disclosure, dated November 17, 2026, clarifies that the execution of the LOI does not constitute a related party transaction. AstraZeneca Pharma India and Strand Life Sciences are not related parties under applicable corporate governance norms.

Praveen Rao Akkinepally, Country President & Managing Director, AstraZeneca Pharma India, said “The continued growth demonstrates the strength of AstraZeneca’s science-led portfolio and our ability to translate innovation into meaningful impact for patients in India. We are accelerating our efforts across oncology, biopharmaceuticals and rare disease.” 

Comments

× Your session has expired. Please click here to Sign-in or Sign-up

Have an Account?

OR

Forgot your password?

OR

First Name should not be empty!

Last Name should not be empty!

Email address should not be empty!

Show Password should not be empty!

Show Confirm Password should not be empty!

Newsletter

E-magazine

Biospectrum Infomercial

Bio Resource

I accept the terms & conditions & Privacy policy